Trifluoperazine induces cellular apoptosis by inhibiting autophagy and targeting NUPR1 in multiple myeloma.
Apoptosis
/ drug effects
Autophagy
/ drug effects
Basic Helix-Loop-Helix Transcription Factors
/ genetics
Cell Cycle
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
China
Humans
Multiple Myeloma
/ drug therapy
Neoplasm Proteins
/ genetics
Sirolimus
/ pharmacology
Trifluoperazine
/ metabolism
apoptosis
autophagy
multiple myeloma
nuclear protein 1
trifluoperazine
Journal
FEBS open bio
ISSN: 2211-5463
Titre abrégé: FEBS Open Bio
Pays: England
ID NLM: 101580716
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
03
04
2020
revised:
11
07
2020
accepted:
17
07
2020
pubmed:
19
8
2020
medline:
24
11
2021
entrez:
19
8
2020
Statut:
ppublish
Résumé
Multiple myeloma (MM) is the second most common hematologic malignancy of immunoglobulin-secreting plasma cells. Recent modern combination therapies have improved survival rates, but many patients develop resistance to novel drugs, leading to relapse. Trifluoperazine (TFP), a typical antipsychotic drug, has been reported to exert antitumor effects by targeting various pathways. Thus far, the role of TFP in MM has not been elucidated. In the current study, we demonstrated that TFP inhibited cell growth and autophagy activity but induced apoptosis of U266 and RPMI 8226 MM cells. Furthermore, cotreatment of these cell lines with TFP and rapamycin, a potent autophagy inducer, reduced cell apoptosis compared with TFP treatment alone. We also found that TFP inhibited nuclear protein 1 (NUPR1) expression. In the presence of TFP, cells stably overexpressing NUPR1 showed a higher viability than cells treated with the nonspecific control. Autophagy suppression and apoptosis induction caused by TFP were also reversed in MM cells upon NUPR1 overexpression. Overall, our results indicate that in the context of MM, TFP targets NUPR1, inhibiting cell growth and inducing apoptosis by autophagy inhibition. Our results could contribute toward efforts for the development of more effective therapies for MM to be tested in future clinical trials.
Identifiants
pubmed: 32810364
doi: 10.1002/2211-5463.12960
pmc: PMC7530380
doi:
Substances chimiques
Basic Helix-Loop-Helix Transcription Factors
0
NUPR1 protein, human
0
Neoplasm Proteins
0
Trifluoperazine
214IZI85K3
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2097-2106Informations de copyright
© 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Références
Int J Mol Sci. 2019 Jun 30;20(13):
pubmed: 31262032
Sci Rep. 2018 Jan 18;8(1):1147
pubmed: 29348654
Cells. 2019 Nov 17;8(11):
pubmed: 31744261
Sci Rep. 2016 Jun 09;6:27540
pubmed: 27277973
J Exp Clin Cancer Res. 2017 Sep 5;36(1):118
pubmed: 28870216
Biomacromolecules. 2019 Jul 8;20(7):2567-2576
pubmed: 31181156
J Mol Model. 2014 Aug;20(8):2357
pubmed: 25056123
Pharmacol Rep. 2012;64(1):16-23
pubmed: 22580516
J Clin Immunol. 2016 May;36 Suppl 1:18-24
pubmed: 26984755
Eur J Pharm Sci. 2006 Jul;28(4):300-6
pubmed: 16707254
Oncol Rep. 2018 Sep;40(3):1487-1494
pubmed: 30015974
Leuk Res. 2017 Aug;59:97-104
pubmed: 28599191
Curr Gene Ther. 2002 Feb;2(1):45-55
pubmed: 12108973
J Clin Invest. 2019 Mar 28;129(6):2500-2513
pubmed: 30920390
FASEB J. 2019 Aug;33(8):8836-8852
pubmed: 31067083
DNA Cell Biol. 2020 Mar;39(3):368-378
pubmed: 31971825
Cancers (Basel). 2019 Nov 26;11(12):
pubmed: 31769431
Med Sci Monit. 2019 May 02;25:3247-3255
pubmed: 31048671
Int J Cancer. 2019 May 15;144(10):2613-2624
pubmed: 30488605
Nat Rev Cancer. 2016 Jan;16(1):20-33
pubmed: 26678314
J Natl Compr Canc Netw. 2018 Jan;16(1):11-20
pubmed: 29295877
Theranostics. 2019 Apr 13;9(8):2361-2379
pubmed: 31149049
Oncol Rep. 2020 Feb;43(2):681-688
pubmed: 31922247
Autophagy. 2018;14(4):654-670
pubmed: 29130426
Haematologica. 2018 Feb;103(2):197-211
pubmed: 29217780
J Cell Biochem. 2019 Sep;120(9):15756-15765
pubmed: 31081173
Redox Biol. 2019 Jan;20:467-482
pubmed: 30466060